Monoclonal Antibodies—Therapeutic and Diagnostic Uses in Malignancy

Por Lowder, James N., Levy, Ronald
Publicado em 1985

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates

Por Wong, Michael K, Daniels, Gregory A, Kaufman, Howard L, McDermott, David F, Morse, Michael A, Aung, Sandra, Lowder, James N
Publicado em 2013

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

Por Wong, Michael K, Kaufman, Howard L, Daniels, Gregory A, McDermott, David F, Aung, Sandra, Lowder, James N, Morse, Michael A
Publicado em 2014

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

Por Kaufman, Howard L., Wong, Michael K., Daniels, Gregory A., McDermott, David F., Aung, Sandra, Lowder, James N., Morse, Michael A.
Publicado no J Pers Med (2014)

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Por Alva, Ajjai, Daniels, Gregory A., Wong, Michael K. K., Kaufman, Howard L., Morse, Michael A., McDermott, David F., Clark, Joseph I., Agarwala, Sanjiv S., Miletello, Gerald, Logan, Theodore F., Hauke, Ralph J., Curti, Brendan, Kirkwood, John M., Gonzalez, Rene, Amin, Asim, Fishman, Mayer, Agarwal, Neeraj, Lowder, James N., Hua, Hong, Aung, Sandra, Dutcher, Janice P.
Publicado no Cancer Immunol Immunother (2016)